Literature DB >> 17188790

Noradrenergic facilitation of shock-probe defensive burying in lateral septum of rats, and modulation by chronic treatment with desipramine.

Corina O Bondi1, Gabriel Barrera, M Danet S Lapiz, Tania Bedard, Amy Mahan, David A Morilak.   

Abstract

We have previously shown that acute stress-induced release of norepinephrine (NE) facilitates anxiety-like behavioral responses to stress, such as reduction in open-arm exploration on the elevated-plus maze and in social behavior on the social interaction test. Since these responses represent inhibition of ongoing behavior, it is important to also address whether NE facilitates a response that represents an activation of behavior. Correspondingly, it is unknown how a chronic elevation in tonic steady-state noradrenergic (NA) neurotransmission induced by NE reuptake blockade might alter this acute modulatory function, a regulatory process that may be pertinent to the anxiolytic effects of NE reuptake blockers such as desipramine (DMI). Therefore, in this study, we investigated noradrenergic modulation of the shock-probe defensive burying response in the lateral septum (LS). In experiment 1, shock-probe exposure induced an acute 3-fold increase in NE levels measured in LS of male Sprague-Dawley rats by microdialysis. Shock-probe exposure also induced a modest rise in plasma ACTH, taken as an indicator of perceived stress, that returned to baseline more rapidly in rats that were allowed to bury the probe compared to rats prevented from burying by providing them with minimal bedding, indicating that the active defensive burying behavior is an effective coping strategy that reduces the impact of acute shock probe-induced stress. In experiment 2, blockade of either alpha(1)- or beta-adrenergic receptors in LS by local antagonist microinjection immediately before testing reduced defensive burying and increased immobility. In the next experiment, chronic DMI treatment increased basal extracellular NE levels in LS, and attenuated the acute shock probe-induced increase in NE release in LS relative to baseline. Chronic DMI treatment decreased shock-probe defensive burying behavior in a time-dependent manner, apparent only after 2 weeks or more of drug treatment. Moreover, rats treated chronically with DMI showed no significant rise of plasma ACTH in response to shock-probe exposure. Thus, acute stress-induced release of NE in LS facilitated defensive burying, an active, adaptive behavioral coping response. Chronic treatment with the NE reuptake blocker and antidepressant drug DMI attenuated acute noradrenergic facilitation of the active burying response, and also attenuated the level of perceived stress driving that response. These results suggest that long-term regulation of the acute modulatory function of NE by chronic treatment with reuptake blockers may contribute to the mechanisms by which such drugs exert their anxiolytic effects in the treatment of stress-related psychiatric conditions, including depression and anxiety.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188790     DOI: 10.1016/j.pnpbp.2006.11.015

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  22 in total

1.  Corticotropin-releasing factor in the norepinephrine nucleus, locus coeruleus, facilitates behavioral flexibility.

Authors:  Kevin Snyder; Wei-Wen Wang; Rebecca Han; Kile McFadden; Rita J Valentino
Journal:  Neuropsychopharmacology       Date:  2011-10-12       Impact factor: 7.853

2.  Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling.

Authors:  M J Skelly; A E Chappell; E Carter; J L Weiner
Journal:  Neuropharmacology       Date:  2015-06-01       Impact factor: 5.250

Review 3.  Prefrontal cortex executive processes affected by stress in health and disease.

Authors:  Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-07-06       Impact factor: 5.067

4.  Therapeutic Effects of Extinction Learning as a Model of Exposure Therapy in Rats.

Authors:  Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Neuropsychopharmacology       Date:  2016-07-15       Impact factor: 7.853

5.  Maternal defense is modulated by beta adrenergic receptors in lateral septum in mice.

Authors:  Melissa-Ann L Scotti; Grace Lee; Stephen C Gammie
Journal:  Behav Neurosci       Date:  2011-06       Impact factor: 1.912

6.  Chronic desipramine treatment alters tyrosine hydroxylase but not norepinephrine transporter immunoreactivity in norepinephrine axons in the rat prefrontal cortex.

Authors:  Susan L Erickson; Anjalika R Gandhi; Josephine K Asafu-Adjei; Allan R Sampson; LeeAnn Miner; Randy D Blakely; Susan R Sesack
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-06       Impact factor: 5.176

7.  Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats.

Authors:  Gregory V Carr; Lee E Schechter; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2010-03-09       Impact factor: 4.530

8.  Early adolescence as a critical window during which social stress distinctly alters behavior and brain norepinephrine activity.

Authors:  Brian Bingham; Kile McFadden; Xiaoyan Zhang; Seema Bhatnagar; Sheryl Beck; Rita Valentino
Journal:  Neuropsychopharmacology       Date:  2010-12-22       Impact factor: 7.853

9.  Effects of chronic plus acute prolonged stress on measures of coping style, anxiety, and evoked HPA-axis reactivity.

Authors:  Megan K Roth; Brian Bingham; Aparna Shah; Ankur Joshi; Alan Frazer; Randy Strong; David A Morilak
Journal:  Neuropharmacology       Date:  2012-07-25       Impact factor: 5.250

10.  Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats.

Authors:  M D S Lapiz-Bluhm; C O Bondi; J Doyen; G A Rodriguez; T Bédard-Arana; D A Morilak
Journal:  J Neuroendocrinol       Date:  2008-07-30       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.